Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.764
EU - Europa 4.280
AS - Asia 3.706
SA - Sud America 579
Continente sconosciuto - Info sul continente non disponibili 474
AF - Africa 99
OC - Oceania 8
Totale 19.910
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.605
SG - Singapore 1.439
RU - Federazione Russa 1.107
CN - Cina 977
IT - Italia 755
FI - Finlandia 658
DE - Germania 444
BR - Brasile 433
HK - Hong Kong 334
VN - Vietnam 293
UA - Ucraina 213
PL - Polonia 200
GB - Regno Unito 194
IE - Irlanda 183
FR - Francia 165
JP - Giappone 126
SE - Svezia 123
KR - Corea 111
IN - India 104
CA - Canada 98
BD - Bangladesh 64
RO - Romania 56
AR - Argentina 48
BE - Belgio 47
TR - Turchia 44
IQ - Iraq 42
NL - Olanda 30
CI - Costa d'Avorio 27
ES - Italia 25
MX - Messico 24
VE - Venezuela 23
EC - Ecuador 22
UZ - Uzbekistan 21
AT - Austria 20
CO - Colombia 19
ZA - Sudafrica 18
MA - Marocco 17
IR - Iran 16
MY - Malesia 16
CH - Svizzera 14
PH - Filippine 14
ID - Indonesia 11
PK - Pakistan 11
SA - Arabia Saudita 11
CL - Cile 10
LB - Libano 10
UY - Uruguay 9
DZ - Algeria 8
NP - Nepal 8
CR - Costa Rica 7
KE - Kenya 7
KZ - Kazakistan 7
PY - Paraguay 7
AU - Australia 6
CZ - Repubblica Ceca 6
EG - Egitto 6
IL - Israele 6
JM - Giamaica 6
PE - Perù 6
TW - Taiwan 6
EU - Europa 5
JO - Giordania 5
LU - Lussemburgo 5
PS - Palestinian Territory 5
TN - Tunisia 5
AL - Albania 4
AZ - Azerbaigian 4
BY - Bielorussia 4
HU - Ungheria 4
LT - Lituania 4
PA - Panama 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
ET - Etiopia 3
GA - Gabon 3
GR - Grecia 3
KG - Kirghizistan 3
QA - Qatar 3
BG - Bulgaria 2
BH - Bahrain 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GE - Georgia 2
HN - Honduras 2
LV - Lettonia 2
NO - Norvegia 2
RS - Serbia 2
SI - Slovenia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AO - Angola 1
BN - Brunei Darussalam 1
BW - Botswana 1
CU - Cuba 1
CY - Cipro 1
Totale 19.427
Salva come PNG Salva come JPEG
Città #
Fairfield 1.439
Ashburn 1.283
Singapore 938
Woodbridge 765
Seattle 576
Wilmington 576
Chandler 572
Houston 547
Cambridge 527
Ann Arbor 494
San Jose 494
Hong Kong 324
Moscow 201
Palermo 186
Dublin 175
Zgierz 170
Council Bluffs 169
Beijing 167
Santa Clara 146
Medford 142
Des Moines 130
Los Angeles 126
Altamura 118
Tokyo 114
Nanjing 112
Helsinki 109
Jacksonville 108
New York 103
Ho Chi Minh City 97
Boardman 93
Princeton 90
The Dalles 84
Dallas 82
Lawrence 80
Lauterbourg 79
San Diego 73
Frankfurt am Main 72
Hanoi 67
Phoenix 60
Chicago 54
Hefei 52
Dearborn 50
Brussels 46
London 44
São Paulo 44
Tulsa 42
Ludwigshafen am Rhein 39
Buffalo 38
Orem 38
Changsha 37
Seoul 35
Nanchang 33
Shenyang 33
Jiaxing 31
Tianjin 31
Hebei 29
Abidjan 27
Bremen 27
Denver 27
Izmir 26
Munich 25
Panama City 25
Chennai 24
Toronto 24
Da Nang 23
Jinan 23
Nuremberg 23
Warsaw 23
Kitzingen 22
Guangzhou 21
Kumar 21
Milan 20
Saint Petersburg 20
Seongnam 20
Baghdad 19
Montreal 19
Zhengzhou 18
Rome 17
Belo Horizonte 16
Ningbo 16
Brooklyn 15
San Paolo di Civitate 15
Washington 15
Columbus 14
Hangzhou 14
Amsterdam 13
Atlanta 13
Turku 13
Venice 13
Boydton 12
Haiphong 12
Poplar 12
Springfield 12
Stockholm 12
Tashkent 12
Mumbai 11
Rio de Janeiro 11
San Francisco 11
Berlin 10
Shanghai 10
Totale 13.140
Salva come PNG Salva come JPEG
Nome #
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 357
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 349
Dietary restriction: could it be considered as speed bump on tumor progression road? 328
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 317
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations 314
Anti-endothelin drugs in solid tumors 301
Analysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 294
EGF Induces STAT3-Dependent VEGF Expression in HT-29 colon cancer cells 294
A headlight on liquid biopsies: a challenging tool for breast cancer management 290
I tumori della mammella e/o dell’ovaio di tipo eredofamiliare: strategie di prevenzione nelle donne ad alto rischio 279
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense? 278
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 277
BRCA1 and BRCA2 germline mutations in sicilian breast and/or ovarian cancer families and their association with familial profiles 272
BRCA1 and BRCA2 variants of uncertain clinical significance and their implications for genetic counseling 268
How Much of Familial Breast Cancer Risk is Currently Explained by the Known Genes? 267
Targeted Therapies in Hepatocellular Carcinoma 263
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma 263
Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS) patients with epirubicin and ifosfamide 262
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 261
Nintedanib in NSCLC: Evidence to date and place in therapy 261
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment 260
The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies 259
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 259
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 254
Monoclonal antibodies in gastrointestinal cancers 252
HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions 250
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 248
Cancer and the microbiome: Potential applications as new tumor biomarker 247
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 243
Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines 242
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 242
EGFR genomic alterations in cancer: prognostic and predictive values 241
MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness? 241
Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? 240
Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors 238
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 238
MicroRNAs in Colorectal Cancer Drug Resistance: Shooters become Targets 237
Downregulated expression of Cdc25A gene in MCF-7 breast cancer cell 236
The role of targeted therapy for gastrointestinal tumors 235
BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 233
Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy 233
A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients 230
Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer 229
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis 229
HER2-positive male breast cancer: An update 228
Multisciplinary management of patients with liver metastasis from colorectal cancer 226
Sex steroids, carcinogenesis, and cancer progression 225
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 223
A literature-based meta-analysis of the comparison between Gemcitabine-based combination and monochemotherapy for the treatment of advanced non-small cell lung cancer in elderly patients 215
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting 215
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma 210
Well-being among Italian medical oncologists: An exploratory study 210
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 209
Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor 209
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 206
Bortezomib: a new pro-apoptotic agent in cancer treatment. 204
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 204
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? 200
Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy? 200
Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules 200
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 199
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 193
Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer 191
Plasma levels of angiogenetic markers in men candidate to prostate biopsy 186
Studio pilota sul valore predittivo dei livelli plasmatici di 9 fattori angiogenetici nella selezione di pazienti candidati alla biopsia prostatica 186
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 185
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 182
A non common BRAF mutation c1799-1801 delTGA identified in sporadic colon rectal cancer of sicilian patients 181
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma 180
Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers 180
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 177
Comparison between gemcitabine-based combination (G) and single-agent chemotherapy (S) for elderly patients (EP) with advanced non-small cell lung cancer (NSCLC): A literature-based meta-analysis. 173
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 173
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 168
Impact of the new 5-HT3 receptor antagonist palonosetron (P) in chemotherapy-induced nausea and vomiting (CINV) control in elderly advanced breast cancer (EABC) patients: Comparison with the classic antiemetic agent ondansetron (O). 166
Low dose splenic irradiation in myelofibrosis: outcomes and toxicity of three radiation schedule 162
How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer? 161
An all-oral combination regimen of vinorelbine and capecitabine for elderly patients with metastatic breast cancer 158
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 158
Serum levels of angiogenetic cancer biomarkers in men undergoing prostate biopsy. Preliminary data 157
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 156
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 155
Capecitabine (XEL) + Oxaliplatin (OX) in elderly people (EP) with Colorectal Cancer (CRC): Comparison of safety (S) and feasibility (F) of two different schedules. Preliminary findings 148
Apoptosis in Thyroid Autoimunity. 147
Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility? 147
Efficacy of weekly low-dose chemotherapy in elderly women with advanced ovarian cancer: is there an antiangiogenic effect? 146
VIPoma and PPoma 146
Ramucirumab and its use in gastric cancer treatment 142
Safety and efficacy of two different schedules of capecitabine combined with oxaliplatin in the treatment of colon cancer in the elderly 106
RECHALLENGE WITH ANTI-EGFR MONOCLONAL ANTIBODIES IN PRETREATED METASTATIC COLORECTAL CANCER PATIENTS: BEYOND THE LIMITS OF ACQUIRED RESISTANCE 106
Totale 19.910
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.076
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.076
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.259 0 284 72 64 63 50 72 86 117 153 102 196
2022/20231.649 176 354 31 197 183 230 109 110 154 6 67 32
2023/2024666 29 87 51 51 47 132 64 86 7 10 9 93
2024/20251.855 25 151 184 136 60 66 111 190 99 190 250 393
2025/20266.225 523 200 329 474 626 916 810 733 449 694 223 248
2026/2027439 367 72 0 0 0 0 0 0 0 0 0 0
Totale 19.910